About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 32 record(s)
Nothing to report this month
Organization: Natural Sciences and Engineering Research Council of Canada
Nothing to report this month
Organization: Patented Medicine Prices Review Board Canada
Req # A-2022-00020
All documents between Natural Sciences and Engineering Research Council and universities from March 1 2021 to January 1 2023, as part of the Government of Canada-Universities Working Group.Organization: Natural Sciences and Engineering Research Council of Canada
July 2023
Req # A-2022-05111
Electronic copies of the following documents. In all cases, cabinet confidences may be excluded and draft versions of documents. In all of the requests below, “draft guidelines” refers to the PMPRB Guidelines that were published for comment on October 6, 2022, or any prior drafts or versions of those 2022 Guidelines (for example, if a draft version was circulated to Health Canada for comment in September 2022, it would be part of the “draft guidelines” for the purpose of this request). • Emails or other communications from Health Canada commenting on the draft guidelines, and that were sent between July 1, 2022, and October 6, 2022. • Emails or other communications from the Board members or Board Chair commenting on the draft guidelines, and that were sent between July 1, 2022, and October 6, 2022. • Any training presentations, training manuals, or summaries of the new guidelines prepared for use by the Board Staff, Board, or other governmental departments prepared between July 1, 2022, and October 6, 2022. • Any documents with calculations of how much prices will decrease under the draft guidelines, or under alternative pricing rules, and that were prepared between January 1, 2022, and October 6, 2022 (note the change in date relative to other requests). • Any documents comparing prices or price reductions under the draft guidelines and the old PMPRB Compendium of Guidelines and Procedures. • Any documents, including legal memos, on the compliance of the draft guidelines with legal decisions about the PMPRB, including Alexion Pharmaceuticals Inc. v. Canada (Attorney General), 2021 FCA 157, Merck Canada c Canada, 2022 QCCA 240, and Innovative Medicines Canada v. Canada (Attorney General), 2020 FC 725. • Any documents which discuss how a medicine’s therapeutic class and comparator products will be established under the draft guidelines. • Any documents showing how the Board Staff arrived at the exact pricing tests discussed in paragraph 33-35 of the draft Guidelines. • Any documents which discuss how Board Staff will assess whether a price is excessive *after* an investigation has been opened. For context, the backgrounder which accompanied the draft guidelines suggested that staff will consider “the totality of the circumstances surrounding the price of the medicine, through the lens of the section 85 factors.Organization: Patented Medicine Prices Review Board Canada
July 2023
Req # A-2023-025211
With regard to the c. 2003 HDAP Report on New Patented Drug - Angiomax (http://www.pmprbcepmb.gc.ca/view.asp?ccid=583), I am looking for a copy of any supporting research, reports and calculations used to determine dosage regimens. I am specifically interested in how these quantities (in mL) were derived, the benchmark patient weight that was used (in kg) and the timeframe of the dosing.Organization: Patented Medicine Prices Review Board Canada
July 2023
Req # A-2023-025599
For FY 2015-2022 (inclusive), how many investigations into prescription pricing on the basis that the pricing exceeded the guidelines resulted in a public hearing? Of those that resulted in a public hearing, in how many was the pricing found to be excessive? Of those that were found to be excessive, how many resulted in orders to reduce the prescription price?Organization: Patented Medicine Prices Review Board Canada
July 2023
Req # A-2023-025896
For fiscal years 2015-2022 (inclusive), how many new patented medicines were reported to the board by Bayer, Inc.? From among those reports, how many included claims that a price exceeded the guidelines?Organization: Patented Medicine Prices Review Board Canada
July 2023
Req # A-2023-025600
For FY 2015-2022 (inclusive), how many Advance Certificate Rulings were issued by the board?Organization: Patented Medicine Prices Review Board Canada
July 2023
Req # A-2020-00025
Corporate data files for the Canada Graduate Scholarship competition (CGS-M and CGS-D) and Postdoctoral Fellowship program: Success rates, by institution, by discipline, and Institutional quotas/allocations from 2010-2020; Scoring sheets and reviewer guidelines 2010-2020; CGS-D and Postdoctoral Fellowship recipients who received an award(s) in a lower level Tri-Council competition from 2010-2020; CIHR policy on how institutional quotas/allocations for CGS-M and CGS-D are calculated; map/flowchart of application process through Tri-Council adjudication for CGS-M and CGS-D; Success rate for the Postdoctoral Fellowship competition from 2010-2020.Organization: Natural Sciences and Engineering Research Council of Canada
January 2023
Req # A-2022-09060
Recordings or transcripts of both of the French language webinars given by the PMPRB on November 8th, 2022, including any audience questions and the PMPRB's responses. Copies of the English and French PowerPoint for the industry specific webinars held on November 8th, 2022.Organization: Patented Medicine Prices Review Board Canada
January 2023